Skip to main content
HR 2562 115th Congress House Health Administrative remedies Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Government information and archives Prescription drugs

Making Pharmaceutical Markets More Competitive Act

Introduced: May 19, 2017 Introduced by: Kelly, Mike Republican · Pennsylvania See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 26, 2017
Referred to the Subcommittee on Health.
May 19, 2017
Referred to the House Committee on Energy and Commerce.
May 19, 2017
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Making Pharmaceutical Markets More Competitive Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs.

The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.

The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.

What's happening now May 26, 2017

Referred to the Subcommittee on Health.

 Related & companion bills 2
  • S 934 Related bill FDA Reauthorization Act of 2017
  • S 1115 Identical bill Making Pharmaceutical Markets More Competitive Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2562: Making Pharmaceutical Markets More Competitive Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-2562/
MLA
"H.R. 2562: Making Pharmaceutical Markets More Competitive Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-2562/.
Bluebook (legal)
H.R. 2562, 115th Cong. (2026), https://openamerica.io/bill/115-HR-2562/.
Markdown link
[H.R. 2562: Making Pharmaceutical Markets More Competitive Act](https://openamerica.io/bill/115-HR-2562/)
Report a problem